Celltran and Xcellentis successfully complete merger

Sheffield (United Kingdom), and Gent (Belgium), October 2, 2006 – Celltran Limited, and
Innogenetics are pleased to jointly announce today that Celltran has successfully
completed its merger with Xcellentis, a subsidiary of Innogenetics, the Belgium based
international biopharmaceutical company. Through the transaction, Celltran has acquired
the assets of Xcellentis and Innogenetics has received shares and warrants in the capital
of Celltran which will ultimately lead to Innogenetics owning a 51% stake in Celltran.
Celltran is a UK biotechnology company specialising in developing autologous cell therapy
products and services to heal wounds. The Company’s lead product, Myskin™, currently
generating revenues and marketed in the UK through an established sales and distribution
network will be especially complemented by the Xcellentis active wound care portfolio.
Lyphoderm™, which will shortly enter Phase 3 clinical trials, consists of freeze-dried skin cells of allogeneic (donor-derived) origin with enhanced storage, shelf-life, and easy application
properties. In addition, two further therapies from Xcellentis are close to obtaining marketing
approval.

The combination of an experienced management team together with a portfolio comprising
marketed and late development stage products, innovative technology platforms, supported by strong intellectual property, positions Celltran to effectively target the rapidly growing active therapy sector of wound care that is estimated to be worth £4 billion per year worldwide and to seek additional financing to support its growth plans.
Following the merger, Frank Morich, CEO Innogenetics, and Christian Matton, VP Legal & IP of Innogenetics, will join the Board of CellTran as Non-executive Directors.
Commenting on the merger, Mal Jarmolowicz, Chief Executive Officer of Celltran, said: “We are delighted to have sucessfully completed this merger. Through the integration of Xcellentis’ innovative wound care therapies, Celltran now has the strengthened capability to take a distinct, multi-stream approach to the fast growing active wound care sector. The newly combined products demonstrate a strong economic case for use and have a defined route to market, providing Celltran with a robust strategy for moving the business forward.”
Frank Morich, Chief Executive Officer of Innogenetics, added: “We are extremely enthusiastic
about the prospects of combining the activities, technologies, and pipelines of Celltran and
Xcellentis. We have created a specialist wound care powerhouse with a range of new-generation products which include both autologous and allogeneic approaches, that not only offer new solutions to medical needs, but create excellent value for both Innogentics and Celltran’s shareholders.”